A 53-week, open-label phase IIIb study of velaglucerase alfa in Chinese patients with type 1 Gaucher disease: Safety, efficacy, and pharmacokinetics
Author:
Lihui Zhang,Xue-Qun Luo,Yongjun Fang,Fengkui Zhang,Yan Meng,Xiaoping Luo,Liansheng Zhang,Zhengqing Qiu,Xiao Ge,Jaco Botha,Jenny Zhan,Tianyou Wang
Publication:
Molecular Genetics and Metabolism Reports
© 2026 Takeda Pharmaceuticals International AG. Published by Elsevier Inc.